Abstract: A method for treating and/or preventing certain ailments by administering to a person in need thereof L-?-lysophosphatidylcholine as an agent for activating the immune system of the person. Also, vaccine compositions that include L-?-lysophosphatidylcholine.

Abstract: The present invention relates to methods for screening compounds for treating and/or preventing an Hepatitis C Virus (HCV) infection.

Abstract: Uses, methods and compositions for modulating replication of viruses of the Flaviviridae family, such as hepatitis C virus, through the farnesoid X receptor (FXR) activation or inhibition. More specifically, the use of an antagonist of FXR or an inhibitor of expression thereof for the manufacture of a medicament intended for treating a Flaviviridae virus infection in a subject in need thereof. The use of antagonists of FXR, such as guggulsterone, or use of inhibitors of FXR expression. A cell culture system allowing the replication of HCV and to methods for diagnosing HCV infection, screening of anti-viral compounds and vaccine or viral protein production.

Abstract: The disclosure relates to a method for in vivo differentiation of monocytes in mature dendritic cells, wherein a) monocytes are provided in an appropriate culture medium, b) the monocycles are differentiated in dendritic cells in the presence of a differentiation factor, c) L-?-lysophosphatidylcholine is added to the medium and mature dendritic cells are obtained. The disclosure also relates to the use of at least one inhibitor of L-?-lysophosphatidylcholine in the production of a medicament for the prevention of an inflammation and/or in order to combat an inflammatory disease and/or autoimmune disease.

Abstract: The present invention relates to the use of L-?-lysophosphatidylcholine and/or an equivalent compound for the differentiation of monocytes into mature denditric cell. The present invention also relates to a method for differentiation monocytes into mature denditric cells according to which monocytes are provided in a medium suitable for their differentiation and L-?-lysophosphatidylcholine and/or an equivalent compound is added to said medium.

Abstract: The invention concerns a method for differentiating precursor cells into mature dendritic cells, comprising placing the precursor cells in a medium suitable for their differentiation and adding to the medium, in a predetermined amount, at least one fraction of oxidized lipoproteins selected among oxidized very low density lipoproteins (VLDLs) and/or oxidized intermediate density lipoproteins (IDLs) and/or oxidized low density lipoproteins (LDLs). The precursor cells are preferably monocytes.

Abstract: The invention concerns a method for HVC virus culture in vitro comprising steps which consist in: contacting particles containing hepatitis C virus RNA with cells capable of synthesizing and secreting lipoproteins, in a suitable culture environment promoting synthesis and secretion of lipoproteins, and in collecting the virus thus obtained. The invention has diagnostic and therapeutic applications.

Abstract: The invention concerns a method of culturing, propagating and replicating in vitro viruses of the Togaviridae and Flaviviridae families which consists in: providing at least a fraction of LVP's obtained from serum or plasma of a patient infected with a least a virus of the Togaviridae and Flaviviridae families; contacting said fraction, for a predetermined time interval in an appropriate culture medium, with permissive cells having an endocytosis path relayed by at least one receptor of the lipoproteins and modulated inter alia by an activating agent selected among an unsaturated fatty acid or an unsaturated fatty acid derivative comprising 16 to 20 carbon atoms or their mixture. The invention also concerns the uses of viral particles and polypeptides obtained by said method.

Abstract: The invention concerns the use of at least a fraction of oxidised (VLDL oxidised and/or IDL oxidised and/or LDL oxidised) lipoproteins for differentiating precursor cells into mature dendritic cells. The precursor cells are preferably monocytes. The invention also concerns a method for differentiating precursor cells into mature dendritic cells which consists in placing the precursor cells in a medium suitable for their differentiation and adding to said medium, in a predetermined amount, at least a fraction of oxidised lipoproteins selected among VLDL oxidised or IDL oxidised n or LDL oxidised lipoproteins. The precursor cells are preferably monocytes.

Abstract: In accordance with the invention, there is provided a method for preventing or treating a disease associated with abnormal cell proliferation, or for modulating or controlling apoptosis, wherein the method comprises administering to a patient in need of such treatment an effective amount of at least one human immunodeficiency virus (HIV) protease inhibiting compound, in particular ritonavir, saquinavir, or one of their pharmaceutically acceptable salts, in combination with a pharmaceutically acceptable vehicle. The method will thus be especially useful in treating diseases resulting from abnormal cell proliferation such as cancer.

Abstract: The complex consists of LVPs associated with human immunoglobulins having a density of less than 1.063 g/ml. It may be obtained by a method according to which a plasma or serum sample taken from a patient infected with HCV is made available, the LVPs are separated from the said sample by centrifugation according to their density, and the LVPs associated with human immunoglobulins are separated using protein A, anti-human immunoglobulins or any other molecule capable of binding human immunoglobulins.

Abstract: The invention relates to the use of at least one compound that inhibits HIV (human immunodeficiency virus) protease, selected from ritonavir, saquinavir or one of the pharmaceutically acceptable salts thereof, in association with a pharmaceutically acceptable vehicle for the production of a medicament to modulate proteasome.

Abstract: The complex consists of LVPs associated with human immunoglobulins having a density of less than 1.063 g/ml.